1. Home
  2. SY vs CRBP Comparison

SY vs CRBP Comparison

Compare SY & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo So-Young International Inc. American Depository Shares

SY

So-Young International Inc. American Depository Shares

N/A

Current Price

$2.04

Market Cap

195.2M

Sector

Technology

ML Signal

N/A

CRBP

Corbus Pharmaceuticals Holdings Inc.

N/A

Current Price

$3.41

Market Cap

190.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SY
CRBP
Founded
2013
2009
Country
China
United States
Employees
2348
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
195.2M
190.3M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
SY
CRBP
Price
$2.04
$3.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
10
Target Price
$7.34
★ $33.22
AVG Volume (30 Days)
186.3K
★ 1.1M
Earning Date
11-24-2026
11-09-2026
Dividend Yield
★ 1.37%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $4,822,272.00
Revenue This Year
$34.60
N/A
Revenue Next Year
$36.03
$131.00
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 97.62
52 Week Low
$1.28
$2.81
52 Week High
$3.90
$12.88

Technical Indicators

Market Signals
Indicator
SY
CRBP
Relative Strength Index (RSI) 39.66 34.65
Support Level $1.91 $2.81
Resistance Level $2.07 $8.13
Average True Range (ATR) 0.11 0.43
MACD 0.01 0.11
Stochastic Oscillator 30.24 39.54

Price Performance

Historical Comparison
SY
CRBP

About SY So-Young International Inc. American Depository Shares

So-Young International Inc is an aesthetic treatment platform in China connecting consumers with online services and offline treatments. Its online platform operates across multiple access points, including mobile app, Weixin mini program, and soyoung.com website, where both consumers and aesthetic practitioners can access media content, an engaging social community and a transparent reservation system. The company has four reportable segments: Aesthetic treatment services group, Platform service group, Wuhan Miracle, and Others. The majority of revenue is derived from the Platform service group, which generates revenue by providing information services and reservation services. All the company's revenues are derived from within the PRC.

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Share on Social Networks: